Aerocrine resumes sales and marketing of NIOX MINO® in China after re-registration approval

Solna (Sweden) – December 15, 2014 – Aerocrine AB (OMX Nordic Exchange: AERO), a
leader in products to monitor and manage airway inflammation associated with
Asthma, announced today that its handheld airway inflammation monitoring device,
NIOX MINO®, has been re-registered for marketing and sales by the China Food and
Drug Administration (CFDA). The approval means that Aerocrine and its partners
can now resume its sales and marketing activities of NIOX MINO and grow the
deployed base in the Chinese market.
“The approval is very welcome both for us and for patients with asthma. The
advantages of FeNO (Fractional exhaled Nitric Oxide) testing are well-recognized
and together with key opinion leaders for asthma we will spread the knowledge of
FeNO throughout China. In order to help more patients, we will work to expand
the installed base and continue to promote the test kit utilization at
hospitals. The approval also gives reassurance to our distributors to actively
engage with customers again”, said Scott Myers, CEO, Aerocrine.

The re-registration approval is effective today and means that Aerocrine and its
distributors can immediately reassume sales and marketing of the NIOX MINO in
China. FeNO tests have been approved for PPT (pay-per-test) in 15 of the 32
provinces, which means that the doctors are allowed to charge patients for the
tests. In addition there are currently three regions; i.e. Shanghai City,
Tianjin City, and Guangdong province, that have received reimbursement.
Submissions for reimbursement approvals have also been made in other regions.
For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368
0336
About Aerocrine

Aerocrine AB is a medical products company focused on the improved management
and care of patients with inflammatory airway diseases. As the pioneer and
leader in technology to monitor and manage airway inflammation, Aerocrine
markets NIOX MINO® and NIOX VERO®. Both products enable fast and reliable
management of airway inflammation and may therefore play a critical role in more
effective diagnosis, treatment and follow-up of patients with inflammatory
airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries
in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on
the Stockholm Stock Exchange in 2007.

About asthma

Asthma is a chronic inflammatory disease of the airways characterized by
symptoms including cough, wheezing and difficulty in breathing. Asthma is one of
this world’s most common and costly diseases, affecting 8-10 % of the world
population and always in the top five in terms of costs of chronic diseases.
Since the disease has no cure, proper diagnosis and management are important to
optimize the treatment of a patient’s asthma. Using an Aerocrine FeNO-testing
device offers several advantages for patient care, including improving patient
safety by helping them to maintain adequate control and minimize exacerbations.

Aerocrine may be required to disclose the information provided herein pursuant
to the Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 am on December 15, 2014.